Dr. Douville is Managing Partner and Co-founder of AmorChem, a Québec-based seed venture fund dedicated to financing and commercializing university-based life sciences technologies.  Launched in 2011 with a capital of $41,25M, the AmorChem fund model uniquely combines access to financial resources with a virtual incubator structure that enables the rapid development and commercialization of life science technologies.  The first fund successfully built a portfolio of 24 technologies, leveraged its initial capital to close to $76M with non-dilutive sources, transacted three pharma exits and spun out six biotech companies.  The AmorChem II fund was launched in September of 2017 and now has $53.7M in capital under management with a mandate to invest in both the provinces of Québec and Ontario.

Elizabeth brings to AmorChem a deep and long-standing experience in venture capital investing having been General Partner of GeneChem, a leading North American life sciences venture capital fund manager.  She joined GeneChem in 1997, moving rapidly from Manager to Partner with the different funds under management.  Elizabeth is very involved and active in the life sciences industry, providing guidance and leadership on the boards of several companies and organizations.  In addition to her participation on the boards of portfolio companies Mperia Therapeutics, Corbin Therapeutics, SemaThera and Fairhaven Pharma, she has recently been appointed Chair of Genome Canada; a not-for-profit organization funded by the Canadian Federal Government to support applied genomics.  She is also an active board member of BioCanRx, a Networks of Centers of Excellence for Bio-Therapeutics for Cancer Treatment and is a Member of the CFI, the Canada Foundation for Innovation.

Elizabeth trained as a biochemist, obtaining her PhD from the University of Ottawa and a post-doctoral fellow from the Imperial Cancer Research Fund in London, UK. She also has a business degree from CIREM/HEC.